翻訳と辞書 |
CERC-301
CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated,〔(【引用サイトリンク】 author = Yahoo! Finance )〕 and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.〔(【引用サイトリンク】 author = Yahoo! Finance )〕 A pilot study was published in 2012,〔 and a phase 2 trial was completed in 2014. ==See also==
* Esketamine * Rapastinel * NRX-1074 * AV-101 * ALKS-5461 * NSI-189
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CERC-301」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|